raloxifene has been researched along with Adenocarcinoma, Basal Cell in 1 studies
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grese, TA | 1 |
| Cho, S | 1 |
| Finley, DR | 1 |
| Godfrey, AG | 1 |
| Jones, CD | 1 |
| Lugar, CW | 1 |
| Martin, MJ | 1 |
| Matsumoto, K | 1 |
| Pennington, LD | 1 |
| Winter, MA | 1 |
| Adrian, MD | 1 |
| Cole, HW | 1 |
| Magee, DE | 1 |
| Phillips, DL | 1 |
| Rowley, ER | 1 |
| Short, LL | 1 |
| Glasebrook, AL | 1 |
| Bryant, HU | 1 |
1 other study available for raloxifene and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Topics: Adenocarcinoma; Animals; Binding Sites; Bone and Bones; Breast Neoplasms; Cell Division; Cholesterol | 1997 |